Surrozen, Inc./De (SRZNW) Stock Price & Analysis
Surrozen, Inc./De (SRZNW) rose 0.00% to USD 0.02 as of June 10, 2026 at 14:23 UTC, according to Nexqual real-time market data.
SRZNW last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 7 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.02 (NCM). Source: Nexqual, June 10, 2026 at 14:23 UTC.
Key Statistics (as of June 10, 2026 at 14:23 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.01 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0.02 – 0.02 |
| Volume | 7 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SRZNW)
Nexqual's technical model rates SRZNW "BUY" based on 4 bullish and 2 bearish signals across 66 daily candles, as of June 10, 2026 at 14:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.02) |
| MACD | 0 (negative) |
Analyst Ratings (SRZNW)
Wall Street analysts rate SRZNW "None", per Nexqual as of June 10, 2026 at 14:23 UTC.
| Consensus Rating | None |
|---|
Earnings (SRZNW)
| Revenue Estimate | $869,000 |
|---|
Source: Nexqual, June 10, 2026 at 14:23 UTC.
Financials & Fundamentals (SRZNW)
| Total Revenue | $7.49M |
|---|---|
| Revenue Growth (YoY) | +408.60% |
| Gross Margin | +0.00% |
| Operating Margin | -209.12% |
| Profit Margin | +0.00% |
| Current Ratio | 11.91 |
| Total Cash | $106.91M |
| Total Debt | $6.78M |
| Free Cash Flow | $-26.11M |
Source: Nexqual, June 10, 2026 at 14:23 UTC.
Financial Health Score (SRZNW)
Nexqual rates Surrozen, Inc./De's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:23 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $107M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SRZNW)
| Float | 4.75M |
|---|
Source: Nexqual, June 10, 2026 at 14:23 UTC.
Leadership (SRZNW)
Surrozen, Inc./De is led by Craig C. Parker (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 14:23 UTC.
| CEO, President & Director | Craig C. Parker (age 63) |
|---|---|
| COO & Corporate Secretary | Charles Williams (age 45) |
| Executive Vice President of Research | Yang Li (age 56) |
| Chief Financial Officer | Andrew Maleki (age 35) |
| Senior Vice President of Development Operations | Michael Lauw M.S.W. |
Major Backers & Investors (SRZNW)
Notable institutional backers of Surrozen, Inc./De include Baker Bros. Advisors, LP, LMR Partners LLP, Bridger Management LLC, according to Nexqual as of June 10, 2026 at 14:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 25.95% |
| LMR Partners LLP | 20.19% |
| Bridger Management LLC | 13.77% |
| Euclidean Capital Llc | 5.32% |
| Deerfield Management Company, L.P | 5.19% |
| Perceptive Advisors Llc | 5.19% |
| SymBiosis Capital Partners, LLC | 4.67% |
| ArrowMark Colorado Holdings LLC | 3.37% |
Source: Nexqual, June 10, 2026 at 14:23 UTC.
From Surrozen, Inc./De's Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Technology Our proprietary platform, SWAPs, enables us to potently and selectively modulate Wnt signaling through the generation of Wnt mimetics.
- Vabysmo is one of the market-leading products and generated over $5 billion in global revenue in 2025.
- Branded anti-VEGF therapies for the treatment of retinal diseases, including wet AMD and DME, cumulatively generated over $13 billion in global revenue in 2025.
- The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents targeting VEGF and angiopoietin-2, or Ang-2.
Partnerships
- We have partnered with key thought leaders in the field, including those on our Scientific Advisory Board, and have developed significant expertise in various areas of biology relevant to the Wnt signaling pathway.
- Collaboration and License Arrangements Collaboration and License Agreement with Boehringer Ingelheim International GmbH In October 2022, we executed the CLA with Boehringer Ingelheim to research, develop and commercialize Fzd4 bi-specific antibodies designed using our SWAP technology, including SZN-413.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRZN | Surrozen, Inc. | USD 22.24 | ▲ 7.49% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0.01 | ▼ 33.82% |
| HUMAW | Humacyte, Inc. | USD 0.06 | ▼ 45.45% |
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
| SABSW | SAB Biotherapeutics, Inc. | USD 0.01 | ▼ 72.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:23 UTC. This page is informational and not investment advice.